Microsoft Is Paying Too Much In Capex To Drive Revenue Growth (Archive, Full Access) Microsoft faces impending stock downside as aggressive AI infrastructure expenditures yield negative returns.
Decoding Celestica: How Custom AI Hardware Is The Most Important Catalyst (Archive) Celestica is uniquely positioned to benefit from hyper-scaler custom AI hardware deployment trends.
SpaceX: Is The Starlink TAM Overstated? A Critical Valuation Review (Archive) SpaceX faces significant valuation risks despite its growth potential and Starlink market share.
Marvell: Set To Win From Hyperscalers' Custom Chip Programs (Archive) Marvell is primed for explosive custom AI chip growth, despite premium valuation risks.
Astronics: On The Cusp Of A Production And Upgradation Upcycle (Archive, Full Access) Astronics rides a powerful aircraft production, retrofit, and premium cabin systems upcycle tailwind.
Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy (Archive) Wegovy pill expands US obesity share, but cash flow limits and GLP‑1 competition constrain upside.
AMD: The Market Is Still Underpricing Its AI CPU Super Cycle (Archive, Full Access) AMD’s agentic-AI-driven server CPU and GPU surge is still mispriced by markets.